<div id="readability-page-1"><div><p><span>Shlevin Harold H Director of Galectin Therapeutics Inc [GALT] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><th><span>Date</span></th><th><span>Transaction</span></th><th><span>Shares</span></th><th><span>Price</span></th><th><span>Value</span></th></tr><tr><td><span>12/8/25-12/9/25</span></td><td><span>Planned Exercise(1)(2)</span></td><td><span>171,790</span></td><td><span>$2.27</span></td><td><span>$390,805</span></td></tr><tr><td><span>12/8/25-12/9/25</span></td><td><span>Planned Sale(2)</span></td><td><span>175,790</span></td><td><span>$6.00</span></td><td><span>$1,055,303</span></td></tr></tbody></table></div><p><span>Ending Holdings: 11,206 - Direct</span></p><div><table><tbody><tr><td><span>(1)</span></td><td><span>90,000 shares exercised 5.3 years before expiration date.</span></td></tr><tr><td><span> </span></td><td><span>25,000 shares exercised 8.1 years before expiration date.</span></td></tr><tr><td><span> </span></td><td><span>20,000 shares exercised 6.1 years before expiration date.</span></td></tr><tr><td><span> </span></td><td><span>20,000 shares exercised 7.1 years before expiration date.</span></td></tr><tr><td><span> </span></td><td><span>16,790 shares exercised 2.5 years before expiration date.</span></td></tr><tr><td><span>(2)</span></td><td><span>Executed pursuant to a prearranged trading plan (10b5-1).</span></td></tr></tbody></table></div><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

GALT

<p>Harold H. Shlevin, Director of Galectin Therapeutics Inc, sold 175,790 shares worth $1.1 million, as disclosed in a Form 4 filed with the SEC. The transactions occurred on December 8-9, 2025, under a prearranged trading plan (10b5-1). Shlevin's ending holdings are 11,206 shares. The Washington Service provides insider trading analysis and data services.</p>

Dir Shlevin Sells 175,790 ($1.1M) Of Galectin Therapeutics Inc [GALT]